SEC Filings

Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT^® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

Filing date	Form	Description	View
Jun 22, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-007676.pdf 0001179110-20-007676.rtf 0001179110-20-007676.xls
Jun 11, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-007240.pdf 0001179110-20-007240.rtf 0001179110-20-007240.xls
Jun 08, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-007334.pdf 0001558370-20-007334.rtf 0001558370-20-007334.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Jun 04, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-006982.pdf 0001179110-20-006982.rtf 0001179110-20-006982.xls
May 29, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-007104.pdf 0001558370-20-007104.rtf 0001558370-20-007104.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
May 19, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-006304.pdf 0001179110-20-006304.rtf 0001179110-20-006304.xls
May 15, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-006664.pdf 0001558370-20-006664.rtf 0001558370-20-006664.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
May 14, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-005993.pdf 0001179110-20-005993.rtf 0001179110-20-005993.xls
May 06, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-005283.pdf 0001558370-20-005283.rtf 0001558370-20-005283.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
May 06, 2020	10-Q	Quarterly report which provides a continuing view of a company's financial position	View HTML 0001558370-20-005307.pdf 0001558370-20-005307.rtf 0001558370-20-005307.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Investors & Media

Transformative science, targeted medicines

SEC Filings

Pagination